{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "OBIO",
  "name": "Orchestra BioMed Holdings, Inc.",
  "url": "https://frontierpicks.com/dossiers/OBIO/",
  "json_url": "https://frontierpicks.com/dossiers/OBIO.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "archetype": {
    "code": "a5",
    "n": 5
  },
  "current_thesis": "Orchestra BioMed finished enrolling its Medtronic-partnered BACKBEAT hypertension trial above target; the Q2 2027 primary-endpoint data settle the case, with a quarterly report ~9 November 2026 and an R&D Day on 12 November 2026 before then.",
  "invalidation_trigger": "A weekly close below $5.00, a round-number level under the 2026-10-14 close of $5.64. A delay of the BACKBEAT data presentation past the second quarter of 2027 would separately break the case.",
  "catalyst_date": "2026-11-09",
  "pick": null,
  "themes": [
    "medtech-diagnostics",
    "binary-catalyst-biotech"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "AVIM Therapy is investigational and not approved for sale; Orchestra BioMed has no product revenue from it.",
    "Medtronic, not Orchestra BioMed, plans to file AVIM Therapy marketing applications if BACKBEAT results are positive.",
    "BACKBEAT primary-endpoint data are targeted for the second quarter of 2027; no efficacy readout is expected before then."
  ],
  "source_links": [],
  "body_markdown": "## Current Thesis\nOrchestra BioMed's pivotal BACKBEAT hypertension trial, run with Medtronic, finished enrolling above target, and the primary-endpoint data targeted for the second quarter of 2027 settle the case. The shares closed at $5.78 on 2026-10-27, and the odds of beating the S&P 500 over the next three months still look no better than even because no efficacy result is due in that window.\n\nAdjusted daily closes show the shares 9.0% below the 52-week high of $6.35 (set 2026-10-01, the day of the enrollment announcement). They have recovered from the $5.64 close of 2026-10-14 but remain under the $5.89 close of 2026-09-28, the session before the enrollment news. The shares gained 44.9% over three months, and the 14-day relative strength index (RSI, a momentum gauge where readings near 50 are neutral) stands at 52.9. The narrative is maturing: the enrollment milestone is well known, and the next dated events are the third-quarter report and an investor event, not a clinical readout.\n\n## Bull Case\n- **Enrollment finished over target.** The company reported on 2026-10-01 that 330 patients were randomized at 81 sites in 13 countries as of 2026-09-30, against a 316-patient target and a protocol need of 284 evaluable patients.\n- **The trial is powered for a modest effect.** The same release says BACKBEAT is designed to detect a difference of at least 5 mmHg in 24-hour ambulatory systolic blood pressure, with more than 90% statistical power.\n- **Medtronic carries the regulatory path.** Per the 2026-10-01 release, Medtronic plans to file marketing applications for Atrioventricular Interval Modulation (AVIM) Therapy with the US Food and Drug Administration and other regulators if results are positive.\n- **Cash covers the readout.** Orchestra reported $110.0 million in cash, cash equivalents and marketable securities at 2026-06-30 and projected funding into the fourth quarter of 2027. It then received a $6.1 million milestone from Haemonetics' acquisition of Vivasure Medical, announced 2026-09-15.\n- **Analyst support rose in September.** BTIG upgraded the shares to a Buy rating with a $10 price target on 2026-09-10, as reported by Benzinga.\n\n## Bear Case\n- **The decisive result is months away.** The company targets a late-breaking presentation in the second quarter of 2027, after three-month follow-up and database lock. No efficacy data arrive before then.\n- **The shares have not reclaimed the pre-news close.** The $5.78 close of 2026-10-27 is below the $5.89 close of 2026-09-28, so the enrollment gain is still not fully recovered.\n- **Cash burn is rising.** Operating activities and fixed-asset purchases used $19.6 million in the quarter ended 2026-06-30, up from $15.6 million a year earlier, per second-quarter results released 2026-08-10.\n- **The outcome is binary.** AVIM Therapy is investigational and generates no product revenue for Orchestra. A miss on the 5 mmHg design threshold would remove the main source of value.\n\n## Setup & Price Structure\nThe last adjusted close is $5.78 on 2026-10-27. The 52-week high is $6.35 from 2026-10-01, 9.0% above the last close. The three-month gain of 44.9% is down from 53.3% on 2026-10-14, and the RSI moved from 42.1 to 52.9 over the same span, which reads as neutral momentum.\n\nThe $5.89 close of 2026-09-28 is the nearest reference above the shares. The $5.00 level in the invalidation condition sits below the $5.64 close of 2026-10-14. Moving-average readings are not part of this note. SEC filings show no new documents since the previous note, and no insider sales or share issuance are reported.\n\n## Catalyst Calendar (next 30 days)\n- **~2026-11-09, est.: third-quarter 2026 results.** Earnings Whispers projects this date before the market opens; the company has not confirmed it. The report updates cash, quarterly burn and the runway. Last year's third-quarter report came on 2025-11-10.\n- **2026-11-12: R&D Day in New York.** The company announced on 2026-10-22 a 3:00 pm ET event with a live webcast covering AVIM Therapy and Virtue SAB. It is a presentation event, and BACKBEAT efficacy data are not scheduled for it.\n- **Q2 2027, company target: BACKBEAT primary-endpoint data.** This lies outside the 30-day window and decides the thesis.\n\n## What Would Change Our Mind\nThe case breaks if the company moves the BACKBEAT data presentation past the second quarter of 2027, if the third-quarter report shows higher cash use or a shorter runway than the fourth-quarter 2027 funding projection, or if a share offering is announced before the readout. A weekly close below $5.00 would also end it.\n\nA result showing a between-group systolic blood pressure difference under the 5 mmHg design threshold would remove the main source of value. The case improves on a third-quarter report that holds the runway projection and an R&D Day that adds detail on the regulatory path without changing the timeline.\n\n## Correlation Notes\nOrchestra's value rests on one device program that Medtronic would commercialize, so the shares respond to company-specific trial news. Medtronic's own results are not tied to the stock. The Vivasure milestone from Haemonetics shows a second source of non-dilutive cash, but it is a one-off payment. Moves in small-cap medical-device and clinical-stage names set the background for the shares on days without company news.",
  "first_seen": "2026-09-28",
  "last_analyzed": "2026-10-28T06:00:20+00:00",
  "last_synthesized": "2026-10-28",
  "last_update_source": "watchlist_research",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}